Skip to main content

Journal Club

Tumor/Skull Base

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

Nature Genetics | 2012

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1038/ng.1102

PMID

22286216

PICO

Population

Pediatric patients with diffuse intrinsic pontine gliomas (DIPG) and non-brainstem pediatric glioblastomas (non-BS-PG)

Intervention

Identification of somatic histone H3 mutations (H3F3A p.K27M, H3F3A p.G34R, HIST1H3B p.K27M)

Comparator

Wild-type histone H3 status

Outcomes

Mutation frequency, tumor subtype specificity, molecular characterization

Design

Type

Observational genomic discovery study

Randomized

No

Multicenter

No

Blinded

N/A

Follow-up

N/A

Primary endpoint

Frequency of histone H3 mutations in DIPG and non-BS-PG cohorts

Secondary endpoints

  • Mutation exclusivity patterns
  • Association with clinical features
  • Specificity to pediatric high-grade gliomas

Practice impact

What this means

This 2012 Nature Genetics paper identified recurrent somatic histone H3 mutations in pediatric DIPG and non-brainstem glioblastomas. 78% of DIPGs harbored H3F3A or HIST1H3B K27M mutations, while 22% of non-brainstem glioblastomas had similar mutations plus 14% with G34R mutations. These findings established a molecular signature for pediatric high-grade gliomas distinct from adult counterparts, though clinical implications remain to be determined.

Bottom line

Histone H3 mutations are highly prevalent in pediatric DIPG and define a molecular subtype of pediatric high-grade glioma

Strength of evidence

moderate

Recommendation

consider change

Why it matters

  • First report of somatic histone H3 mutations in pediatric gliomas
  • High frequency (78%) in DIPG suggests diagnostic utility
  • No therapeutic implications yet established

What would change my mind

  • Prospective validation in multi-institutional cohort
  • Demonstration that H3 mutation status predicts treatment response or survival
  • Functional studies showing therapeutic vulnerability

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

High risk: Discovery cohort small (n=7 DIPG), validation cohort retrospective, no independent replication cohort

Confounding

Minimal: Matched germline DNA used to confirm somatic origin, mutations found in pretreatment samples

Missing data

Not applicable: Complete sequencing data reported for targeted regions

Multiplicity

Moderate: Multiple statistical tests for associations (e.g., chromosome 1q gain, receptor tyrosine kinase amplification) without correction

Notes

  • Whole genome sequencing limited to 7 DIPG cases
  • Validation cohort includes 43 DIPG and 36 non-BS-PG

Stats check

NNT

N/A

Effect sizes

  • 78% (39/50) DIPG had H3 mutations
  • 36% (13/36) non-BS-PG had H3 mutations
  • 60% (30/50) DIPG had H3F3A p.K27M

Absolute effects

  • 50 DIPG cases analyzed
  • 36 non-BS-PG cases analyzed
  • 14% (5/36) non-BS-PG had H3F3A p.G34R

Concerns

  • No survival or clinical outcome data reported
  • No comparative statistics for mutation vs wild-type outcomes

External validity

Who it applies to

Pediatric patients with DIPG or non-brainstem glioblastoma undergoing molecular profiling

Who it does not

Adult glioma patients, low-grade pediatric gliomas, non-CNS pediatric tumors

Generalizability notes

  • Single-institution study (St. Jude Children's Research Hospital)
  • No mutations found in adult GBM exome data per paper

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Results

quote

we performed whole genome sequencing of 7 DIPGs and matched germline DNA, and targeted sequencing of an additional 43 DIPGs and 36 non-brainstem paediatric glioblastomas

claim_id

stats_check.effect_sizes

locator

Table 1

quote

DIPG (n=50): H3F3A p.K27M 30 (60%), HIST1H3B p.K27M 9 (18%), All H3 39 (78%)

claim_id

practice_impact.bottom_line

locator

p. 2 Results

quote

78% of DIPGs and 22% of non-BS-PGs contained p.K27M mutation in H3F3A, encoding histone H3.3, or the related HIST1H3B, encoding histone H3.1

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years